Phenotyping of cutaneous toxicities in patients with metastatic malignant melanoma treated with immune checkpoint blockade therapy at a UK tertiary care centre

Clin Exp Dermatol. 2022 Feb;47(2):448-450. doi: 10.1111/ced.14965. Epub 2021 Oct 20.

Authors

W Ye^{1

2}, M Kim², B P Fairfax^{3

4}, N Coupe³, M J Payne³, R N Matin²

Affiliations

¹ Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
² Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
³ Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ The MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

PMID: 34610165
DOI: 10.1111/ced.14965

No abstract available

Publication types

Letter

MeSH terms

Aged
Female
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immune Checkpoint Inhibitors / therapeutic use
Male
Melanoma / drug therapy*
Melanoma / secondary
Middle Aged
Phenotype
Retrospective Studies
Skin Diseases / chemically induced*
Tertiary Care Centers
United Kingdom

Substances

Immune Checkpoint Inhibitors

Grants and funding